Bullfrog AI Holdings, Inc. (BFRG) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Bullfrog AI Holdings, Inc. is an emerging growth company and smaller reporting company focused on using its proprietary AI/ML platform, bfLEAP, to analyze complex data sets in medicine and healthcare. The company aims to de-risk drug development through precision medicine approaches, strategic partnerships, and internal development of licensed drug assets.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,017,553) | $(1,903,794) |
| Net Loss Per Share (Basic & Diluted) | $(0.21) | $(0.26) |
| Operating Expenses | $2,056,620 | $1,965,718 |
| Cash and Cash Equivalents (End of Period) | $3,801,928 | $7,010,717 |
| Net Cash Used in Operating Activities | $(1,798,125) | $(1,901,634) |
| Total Liabilities | $839,397 | $588,090 |
| Stockholders' Equity | $3,246,475 | $6,804,326 |
Material Changes vs. Prior Period
- Revenue: The company generated no revenue in Q1 2025, consistent with Q1 2024. The first commercial revenue ($65,000) was recognized in Q3 2023.
- Operating Expenses: Increased by approximately $91,000 (4.6%) compared to Q1 2024.
- Research & Development: Increased by $24,134 due to higher licensing costs and expanded target discovery efforts.
- General & Administrative: Increased by $66,768 primarily due to increased personnel costs and fringe benefits.
- Liquidity: Cash balance decreased by approximately $1.63 million during the quarter. This contrasts with Q1 2024, which saw a cash increase of $4.39 million driven by a $5.7 million equity offering.
- Debt: Current liabilities increased due to a new short-term insurance financing agreement of $181,797 entered into in February 2025.
Outlook, Risks, and Management Commentary
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. As of March 31, 2025, cash reserves ($3.8 million) are insufficient to fund planned operations for at least one year beyond the filing date.
- Capital Strategy: The company anticipates raising additional capital through equity sales, debt, or licensing. On April 25, 2025, the company entered into an At-The-Market (ATM) sales agreement with BTIG, LLC, allowing for the sale of up to $20 million of common stock.
- Business Developments: In February 2025, the company announced a collaboration with Eleison Pharmaceuticals Inc. regarding novel chemotherapeutic treatments. The company continues to pursue partnerships to monetize its AI platform and licensed drug assets (e.g., Mebendazole formulations, Beta2-spectrin siRNA).
- Internal Controls: The company disclosed that disclosure controls and procedures were not effective as of March 31, 2025, due to unremediated material weaknesses in internal control over financial reporting. Remediation efforts are ongoing, including transitioning accounting processes to an external firm and enterprise platform.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $3.8 million cash balance against current burn rates and the timeline for potential dilution via the new ATM facility.
- Revenue Timeline: Confirm the status of the Eleison Pharmaceuticals collaboration and other potential partnerships to determine when, if ever, recurring revenue will materialize.
- Internal Control Remediation: Monitor progress on fixing material weaknesses in financial reporting, as this impacts the reliability of future filings.
- Licensing Obligations: Review upcoming minimum royalty payments to JHU-APL ($300,000 annually) and other licensees to ensure cash flow can cover these fixed costs.
- Dilution Risk: Assess the impact of outstanding warrants (approx. 7.2 million) and options (approx. 939,000) on future share count and earnings per share.